Feed 2269.HK
22
WuXi Biologics (Cayman) Inc. 2269.HK · HKSE
$44.34 -1.60% (-$0.72)
Depth
- Market cap
- ¥157.1B
- Enterprise value
- ¥150.5B
- P/E
- 31.6x
- Forward P/E
- 28.1x
- PEG
- 0.7x
- P/S
- 6.7x
- P/FCF
- 58.3x
- EV/EBITDA
- 18.5x
- ROIC
- 10.5%
- Gross margin
- 47.5%
- Net margin
- 21.2%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -0.8x
- Beta
- 0.59
- Free float
- 91.1%
Sector
Healthcare
Industry
Biotechnology
CEO
Zhisheng Chen
Employees
14,705
Headquarters
Wuxi
Valuation
Is today's price reasonable?
- What to watch: The share price is above the Bulios Fair Price.
Growth and estimates
Is it growing, and what comes next?
- What speaks for it: Revenue grew by 13% a year over the last 3 years.
- What speaks for it: Analysts expect revenue to grow by 20% this fiscal year.
- What to watch: It missed profit estimates 5 times in the last 8 quarters.
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
- What speaks for it: Out of every 100 CNY of revenue, 21 CNY is left as net profit.
Financial health
Can it carry its debt?
- What speaks for it: It holds more cash than debt: ¥8.91B against ¥2.27B.
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number